logo
Share SHARE
FONT-SIZE Plus   Neg

Gilead Sciences HIV Drug Quad Gets FDA Panel Backing

Gilead Sciences Inc. (GILD) Friday said that its experimental drug for treating HIV, known as Quad, won the backing of an FDA advisory panel.

The Antiviral Drugs Advisory Committee voted 13 to 1 in favor of Quad to treat HIV-1 infection in treatment-naive adults. The drug, which is a four-in-one combination pill of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, is meant to be taken once daily.

While the FDA is not bound by the recommendations of the panel, its guidance is usually considered by the agency. The FDA will take a final decision on the drug by August 27, 2012. Applications for marketing approval of Quad are also pending in Australia, Canada and the European Union. Market experts believe that the drug has potential to become a blockbuster.

"The Quad is the latest example of Gilead's ongoing efforts to develop highly effective and well tolerated single tablet regimens for people living with HIV," said Andrew Cheng, Senior Vice President, HIV Therapeutics and Development Operations, Gilead Sciences.

Quad's new drug application is supported by clinical studies, which met the primary study goals of being non-inferior as compared to other HIV drugs. The Quad was well tolerated with the most common adverse events noted being nausea, diarrhea, upper respiratory track infection and headache.

Currently, Gilead's Atripla is the most-prescribed HIV treatment regimen in the US. For the first quarter of 2012, Atripla sales increased 19 percent to $887.6 million, while sales from Truvada, another HIV drug, increased 13 percent to $758.3 million.

GILD closed Friday's trading on the Nasdaq at $51.84, up $0.59 or 1.15%, on a volume of 9.6 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Federal Communications Commission Chairman Ajit Pai has announced plans to repeal the net neutrality rules implemented under President Barack Obama. Pai, who was appointed by President Donald Trump, said he circulated his draft order to his fellow FCC commissioners Tuesday morning, with the order... Reflecting expectations the House Republican tax reform bill would provide a relatively modest boost to economic growth, a new analysis by the Tax Policy Center found that the legislation would add about $1.3 trillion to the national debt over a decade. Uber has been hit with an $8.9 million civil penalty by Colorado for allegedly allowing drivers with questionable backgrounds to work for the ride-hailing company. The Colorado Public Utilities Commission or PUC said it has issued a Civil Penalty Assessment Notice or CPAN totaling $8.9 million to Rasier LLC, the parent company of Uber.
comments powered by Disqus
Follow RTT